OTCMKTS:ASPCF - Acerus Pharmaceuticals Stock Price, News, & Analysis

$0.0783
0.00 (0.00 %)
(As of 06/24/2019 01:14 PM ET)
Today's Range
$0.0783
Now: $0.0783
$0.0783
50-Day Range N/A
52-Week Range
$0.0781
Now: $0.0783
$0.2631
Volume800 shs
Average Volume532 shs
Market Capitalization$20.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ASPCF
CUSIPN/A
CIKN/A
Phone416-679-0771

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.38 million

Profitability

Net Income$-18,790,000.00
Net Margins-236.97%

Miscellaneous

Employees29
Market Cap$20.45 million
Next Earnings Date8/9/2019 (Estimated)
OptionableNot Optionable

Receive ASPCF News and Ratings via Email

Sign-up to receive the latest news and ratings for ASPCF and its competitors with MarketBeat's FREE daily newsletter.

Acerus Pharmaceuticals (OTCMKTS:ASPCF) Frequently Asked Questions

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:ASPCF) issued its earnings results on Monday, May, 13th. The company reported ($0.02) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The business had revenue of $2.17 million for the quarter. Acerus Pharmaceuticals had a negative return on equity of 674.68% and a negative net margin of 236.97%. View Acerus Pharmaceuticals' Earnings History.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August 9th 2019. View Earnings Estimates for Acerus Pharmaceuticals.

Has Acerus Pharmaceuticals been receiving favorable news coverage?

News stories about ASPCF stock have trended very negative on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acerus Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Acerus Pharmaceuticals.

Who are some of Acerus Pharmaceuticals' key competitors?

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the folowing people:
  • Dr. Nathan Bryson, Chief Scientific Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Edward Gudaitis, Pres , CEO & Director
  • Mr. Robert M. Motz, Chief Financial Officer
  • Mr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acerus Pharmaceuticals' stock price today?

One share of ASPCF stock can currently be purchased for approximately $0.0783.

How big of a company is Acerus Pharmaceuticals?

Acerus Pharmaceuticals has a market capitalization of $20.45 million and generates $7.38 million in revenue each year. Acerus Pharmaceuticals employs 29 workers across the globe.View Additional Information About Acerus Pharmaceuticals.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is http://www.aceruspharma.com/.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The company can be reached via phone at 416-679-0771 or via email at [email protected]


MarketBeat Community Rating for Acerus Pharmaceuticals (OTCMKTS ASPCF)

Community Ranking:  NaN out of 5 ()
Outperform Votes:  0 (Vote Outperform)
Underperform Votes:  0 (Vote Underperform)
Total Votes:  0
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASPCF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASPCF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel